Plain-English translation of NCT05626426 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a device called repetitive transorbital alternating current stimulation (rtACS) to treat glaucoma and other optic nerve diseases. The device delivers gentle electrical stimulation near your eye, and researchers want to see if this can help improve or protect your vision. This is a smaller trial for patients who are interested in this treatment but don't fit the criteria for the main randomized study.
Glaucoma and optic nerve diseases can cause permanent vision loss, and current treatments don't work for everyone. This trial exists to explore whether electrical stimulation might offer a new way to protect the optic nerve and help people keep their sight.
You likely qualify if…
You likely don't qualify if…
You will receive treatment with the electrical stimulation device every other day over an 8-week period. The device is applied near your eye in a non-invasive way. You'll have regular visits to your study doctor to check your vision, eye pressure, and how well you're tolerating the treatment. The study team will monitor you closely to make sure the treatment is safe and effective for you.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Stanford University
Enrollment target
~40 participants
Started
February 2023
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.